A UK-wide study of more than 200 children found that the leukemia left after the first cycle of blinatumomab is the strongest predictor of relapse. The new BlinPredict tool has already shaped UK treatment guidelines.
The FDA has approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia, after a 282-patient trial found it cut the risk of progression or death by 80% compared with chemoimmunotherapy.